1. To determine the safety and efficacy of non-myeloablative allogeneic stem cell
transplantation using rituximab, cyclophosphamide, fludarabine as a preparative regimen
for patients with advanced or recurrent mantle cell lymphoma.
2. To determine factors associated with response and durable remission in patients
receiving rituximab, cyclophosphamide, and fludarabine in preparation for allogeneic
stem cell transplantation.